Comment on

• Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial.

  Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, Goyal A, Gibson M, Mack MJ, Gennevois D, Califf RM, Kouchoukos NT; PREVENT IV Investigators. Alexander JH, et al. JAMA. 2005 Nov 16;294(19):2446-54. doi: 10.1001/jama.294.19.2446. JAMA. 2005. PMID: 16287955 Clinical Trial.
• Gene therapy and vein graft patency in coronary artery bypass graft surgery.

  Conti VR, Hunter GC. Conti VR, et al. JAMA. 2005 Nov 16;294(19):2495-7. doi: 10.1001/jama.294.19.2495. JAMA. 2005. PMID: 16287962 No abstract available.